Dynavax

$9.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+3.30%) Today
-$0.14 (-1.49%) As of 11:27 PM UTC after-hours

Why Robinhood?

You can buy or sell Dynavax and other stocks, options, and ETFs commission-free!

About DVAX

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA. The listed name for DVAX is Dynavax Technologies Corporation Common Stock.

CEO
Ryan Spencer
Employees
231
Headquarters
Emeryville, California
Founded
1996
Market Cap
1.08B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
5.83M
High Today
$9.41
Low Today
$8.75
Open Price
$9.11
Volume
2.25M
52 Week High
$12.44
52 Week Low
$1.80

DVAX News

Benzinga8h

Earnings Preview for Dynavax Technologies

Dynavax Technologies (NASDAQ:DVAX) announces its next round of earnings this Thursday, February 25. Here is Benzinga's everything-that-matters guide for this Th

DVAX Earnings

-$0.56
-$0.37
-$0.19
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.24 per share
Actual
Available Feb 25, After Hours
Preview Earnings Call

You May Also Like

USEQ
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure